Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice.

Beatriz Avilés Maria José SolerLuis Perez-BelmonteAnabel Jimenez MillanFrancisco Rivas RuizMaria Dolores Garcia de Lucas

Published in: Clinical kidney journal (2022)

In this real-world study, patients with T2D and CKD treated with subcutaneous semaglutide for 12 months significantly improved glycemic control and decreased weight. Albuminuria decreased by >50% in patients with macroalbuminuria. The administration of GLP-1RA in patients with T2D and CKD was safe and well tolerated.

Keyphrases

glycemic control
chronic kidney disease
type diabetes
end stage renal disease
weight loss
clinical practice
blood glucose
insulin resistance
rheumatoid arthritis
body mass index
cardiovascular disease
ankylosing spondylitis
weight gain
systemic lupus erythematosus
disease activity
systemic sclerosis